Biotech Values

[mcbio]

ARQL - 1Q14 CC notes

1. It appears that patient recruitment has sped up quite a bit in the Phase 3 METIV-HCC trial for tivantinib as the company said in this CC that they expect to complete patient enrollment in the trial in mid-2015. The prior guidance (unless I misheard before) had been mid-2016 (item 1 of #msg-98336964 ). Pucci mentioned that enrollment picked up in part because a number of trial centers came on board for the first time that had a fresh start and were not impacted by delays from the prior dose reduction like some centers that had started earlier.

2. ARQL expects to end 2014 with between $57M and $60M in cash.

3. The data in the P3 MARQUEE NSCLC trial has still not matured for the EGFR mutant sub-group.

4. Reference to plans to conduct the Phase 1b trial for at least ARQ 092 (the Akt inhibitor) in biomarker subgroups. Sounds like these may include patients with Akt 1 mutation at a minimum. Also mentioned 092 could be tested in orphan indications beyond oncology where patients have an Akt 1 mutation.

5. ARQL thought they would have data from the P2 IST of tivantinib in prostate cancer at the last look but there were not enough events.